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Abstract: Biofilm infections are a global public health threat, necessitating new treatment strategies.
Biofilm formation also contributes to the development and spread of multidrug-resistant (MDR)
bacterial strains. Biofilm-associated chronic infections typically involve colonization by more than one
bacterial species. The co-existence of multiple species of bacteria in biofilms exacerbates therapeutic
challenges and can render traditional antibiotics ineffective. Polymeric nanoparticles offer alternative
antimicrobial approaches to antibiotics, owing to their tunable physico-chemical properties. Here, we
report the efficacy of poly(oxanorborneneimide) (PONI)-based antimicrobial polymeric nanoparticles
(PNPs) against multi-species bacterial biofilms. PNPs showed good dual-species biofilm penetration
profiles as confirmed by confocal laser scanning microscopy. Broad-spectrum antimicrobial activity
was observed, with reduction in both bacterial viability and overall biofilm mass. Further, PNPs
displayed minimal fibroblast toxicity and high antimicrobial activity in an in vitro co-culture model
comprising fibroblast cells and dual-species biofilms of Escherichia coli and Pseudomonas aeruginosa.
This study highlights a potential clinical application of the presented polymeric platform.
Keywords: multidrug resistance; dual-species biofilms; antimicrobials; polymeric nanoparticles
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1. Introduction
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Biofilm infections are a serious health concern due to their high antibiotic tolerance [1].
In the United States alone, approximately 1.7 million hospital-acquired infections are associated with biofilms each year, resulting in ~11 billion USD annual economic burden [2].
Biofilms are communities of bacterial cells embedded in a self-secreted extracellular polymeric substance (EPS) matrix. The complex nature of biofilms promotes development
of drug resistance and its spread [3,4]. The matrix protects resident bacteria against antimicrobial agents and host immune response. Spatial and chemical heterogeneity across
the matrix results in a diversity of phenotypic changes. Furthermore, scarce nutrient and
oxygen supplies in the inner layers of the matrix induce the formation of dormant and
drug-tolerant persister cells [1,5,6]. Taking all these challenges together, biofilms pose
tougher therapeutic challenges than their planktonic counterparts.
Biofilms in most clinically relevant biofilm infections, such as diabetic foot ulcers,
implant-associated infections and pneumonia in cystic fibrosis patients, are composed
of multiple bacterial species [4,7,8]. Interspecies interactions promote co-aggregation,
metabolic cooperation and transfer of resistance genes. Polymicrobial infections play roles
in chronic and recurring infections [4,7,9]. Multi-species biofilms can exacerbate resistance
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species biofilm of DsRed-expressing E. coli and GFP-expressing MRSA was treated for 1
h with coumarin blue-tagged PNP. Micrographs revealed that PNP penetrated the EPS
matrix and disrupted the biofilm as evidenced by a significant decrease in signal coming
matrix and disrupted the biofilm as evidenced by a significant decrease in signal coming
from E. coli and MRSA (Figure 1, Figure S2). The reduction in fluorescence was more
from E. coli and MRSA (Figure 1, Figure S2). The reduction in fluorescence was more
prominent for E. coli than MRSA. A similar trend was observed for biofilm penetration of
prominent for E. coli than MRSA. A similar trend was observed for biofilm penetration of
PNPs into mono-species biofilms of E. coli and MRSA (Figures S3 and S4).
PNPs into mono-species biofilms of E. coli and MRSA (Figures S3 and S4).

Figure 1. Representative 3D views of confocal image stacks of 4-day-old dual-species biofilm of DsRed-expressing E. coli
Figure 1. Representative 3D views of confocal image stacks of 4-day-old dual-species biofilm of DsRed-expressing E. coli
(red channel) and GFP-expressing MRSA (green channel), coumarin blue-tagged PNPs (blue channel) and their overlay
(red channel) and GFP-expressing MRSA (green channel), coumarin blue-tagged PNPs (blue channel) and their overlay
after treating the biofilms for 1 h with 1 μM coumarin blue-tagged PNPs in M9 media.
after treating the biofilms for 1 h with 1 µM coumarin blue-tagged PNPs in M9 media.

2.2. Minimum Biofilm Bactericidal Concentrations of PNPs
2.2. Minimum Biofilm Bactericidal Concentrations of PNPs
The minimum biofilm bactericidal concentrations (MBBC) of PNPs against singleThe minimum biofilm bactericidal concentrations (MBBC) of PNPs against single- and
and dual-species biofilms were evaluated using an established MBBC protocol [28]. Biodual-species biofilms were evaluated using an established MBBC protocol [28]. Biofilms
films were formed by clinical isolates of E. coli, P. aeruginosa, MRSA and Staphylococcus
were formed by clinical isolates of E. coli, P. aeruginosa, MRSA and Staphylococcus epiderepidermidis, and their combinations. PNPs eradicated the dual-species biofilms (Figure 2).
midis, and their combinations. PNPs eradicated the dual-species biofilms (Figure 2). In
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Figure 3. (a) Biomass and (b) bacteria viability of 2-day-old mono- and dual-species biofilms of MRSA IDRL-6169 + E.
IDRL-10366 after 3 h treatment with PNPs. The data shown are averages of triplicates with the error bars indicating sta
ard deviations.
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Figure 3. (a) Biomass and (b) bacteria viability of 2-day-old mono- and dual-species biofilms
IDRL-10366 after
after33hhtreatment
treatmentwith
withPNPs.
PNPs.The
Thedata
datashown
shownare
areaverages
averagesofof
triplicates
with
error
bars
indicating
standIDRL-10366
triplicates
with
thethe
error
bars
indicating
standard
ard
deviations.
deviations.
2.4. Cell Viability in an In Vitro Fibroblast-Dual Species Biofilm Co-Culture

AnViability
in vitro
co-culture
model consisting
of fibroblast
cells and two-species bio
Species Biofilm
Co-Culture
2.4. Cell
in an
In Vitro Fibroblast-Dual
Co-Culture
E. coli
P. aeruginosa
ATCC-19660
was
used
evaluatebiofilms
the safety
cells
of of th
AnDH5α
in vitro and
co-culture
model consisting
of fibroblast
andto
two-species
P. aeruginosa
was
to evaluate
the safety of
the PNPs
towards
mammalian
cellsATCC-19660
while eradicating
Polymeric
nanoparticles
we
E. coli DH5α
and P.
aeruginosa
was used
usedbiofilms.
evaluate
mammalian
cells
while
eradicating
biofilms.
Polymeric
nanoparticles
were
minitowards
biofilms.
nanoparticles
were
minimally toxic towards the fibroblasts, maintaining ~90% viability at the highest con
mally toxic
the fibroblasts,
maintaining
~90%
viability
at the
highest
concentration
imally
toxictowards
towards
maintaining
~90%
viability
at the
highest
concentration
evaluated.
Atthe
thefibroblasts,
same concentration,
PNPs
reduced
bacterial
amounts up to
evaluated.
At
the
same
concentration,
PNPs
reduced
bacterial
amounts
up
tion evaluated. At the same concentration, PNPs reduced bacterial amounts uptoto~6
~6log
log10
10
colony-forming
units
(Figure
4,
Figure
S7).
colony-forming units
units (Figure
colony-forming
(Figure 4,
4, Figure
Figure S7).
S7).

Figure 4. Viability of 3T3 fibroblast cells and E. coli DH5α + P. aeruginosa ATCC-19660 dual-species
biofilms in the co-culture model after 3 h treatment with PNPs. Scatters and lines represent 3T3
fibroblast cell viability. Bars represent log10 of colony-forming units in biofilms. Limit of quantification is 2 log10. Data are averages of triplicates, with error bars indicating standard deviations.
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3. Discussion
The tunable physicochemical properties of polymeric nanoparticles, such as size,
surface charge and hydrophobicity, allow access to a range of antimicrobial modalities,
making them candidates for treating multi-species biofilm infections [14]. In this study,
oxanorbornene-based PNPs mimic antimicrobial peptides, but synthetic approaches enable fabrication of small size of nanoparticles, exhibiting multivalent interactions with
the bacteria, as well as traverse the biofilm EPS matrix. Nanoparticles access a variety
of antibacterial mechanisms, making the barrier to resistance development higher than
for small molecule antibiotics that target specific processes [14–16]. The antimicrobial
PONI-based polymers employed in this work are functionalized synthetic polymers that
consist of cationic trimethylamine (TMA) head groups bridged to the PONI backbone by
hydrophobic alkyl chains. In our previous study, we explored a library of PONI-based
polymers with varying alkyl chain lengths with hydrophobicity and observed the best
activity from the one with a C11 alkyl bridge (PONI-C11 -TMA) [19,24]. PONI-C11 -TMA
self-assembles into polymeric nanoparticles (PNPs), with size ~15 nm, in aqueous solution
due to the amphiphilicity of the system (Figure S1). Positively charged PNPs enable electrostatic interactions with negatively charged bacterial membranes and the EPS matrix. The
hydrophobic portion of the polymer also contributes to its interactions with bacteria and
EPS, making them effective against dual-species biofilms, even at low concentration range.
The broad-spectrum capabilities of PNPs were established using mono- and dual-species
biofilms of clinical isolates of Gram-positive (S. aureus, S. epidermidis) and Gram-negative
(P. aeruginosa, E. coli) bacteria.
Penetration and accumulation at the infectious site are therapeutic challenges due to
the dense biofilm matrix [12,29]. Dual-species biofilms of red fluorescent protein DsRedexpressing E. coli and green fluorescent protein (GFP)-expressing MRSA were treated
with the PNPs tagged with a blue fluorescent dye, coumarin blue. As shown in Figure 1,
coumarin blue-tagged PNPs successfully penetrated across the dual-species biofilm. Reduced fluorescent signals from both E. coli and MRSA after treatment with PNPs demonstrate an ability to target bacteria within the matrix of the complex biofilm. Notably, there
was a higher fluorescent signal reduction for E. coli cells than for MRSA cells, both in the
mono- and dual-species biofilm settings.
PNPs both penetrate and eradicate biofilms. The PNPs demonstrated minimum
biofilm bactericidal concentrations (MBBC) ranging from 8 to 16 µM for dual-species
biofilms, indicating their broad-spectrum activity (Figure 2). The observed penetration
profiles were consistent with the therapeutic efficacy of PNPs against biofilms. The MBBC
values indicate that the activity of PNPs against MRSA IDRL-6169 (MBBC = 16 µM)
is less compared to the other strains tested such as E. coli CD-2 (MBBC = 1 µM). We
hypothesized that this difference in activity could be due to the structural characteristics of
PNPs. PNPs are equipped with long alkyl chains and a cationic anchor group that disrupts
the LPS-rich outer membrane of Gram-negative bacteria more efficiently relative to the
thick peptidoglycan layer of S. aureus [30].
It is important to benchmark new nanotherapeutics against traditional antibiotics.
For this comparison, we determined the MBBC values of gentamicin, a broad-spectrum
antibiotic, against MRSA IDRL-6169 + P. aeruginosa IDRL-11442, and E. coli IDRL-10366 +
P. aeruginosa IDRL-11442 (Figure S5). Dual-species biofilms exhibited increased gentamicin
tolerance: the MBBC of MRSA + P. aeruginosa (2000 µM) was 4-fold higher than that
of P. aeruginosa only (500 µM), and 125-fold higher than that of MRSA only (16 µM).
For P. aeruginosa + E. coli, the MBBC (>4200 µM) was increased by ≥8-fold relative to
P. aeruginosa only (500 µM) and ≥260-fold relative to E. coli only (16 µM). This increase in
required bactericidal concentrations emphasizes hurdles posed by multi-species biofilms
for small molecule antibiotics. In contrast, the dual-species biofilm MBBC values for PNPs
did not significantly increase, with values dictated by the bacterial species with the higher
MBBC value in the mono-species setting. That dual-species biofilms were not more resistant
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than the monocultures indicates an advantage nanotherapeutics may have over traditional
antibiotics.
PNPs were highly effective against preformed, established biofilms. Two-day-old
dual-species biofilms of E. coli IDRL-10366 + MRSA IDRL-6169, and E. coli IDRL-10366
+ P. aeruginosa IDRL-11442 were treated with different concentrations of PNPs for 3 h.
Subsequently, biofilm viability was determined using Alamar Blue assay, and biofilm
biomass was quantified through crystal violet assay. PNPs eradicated bacteria and reduced
biofilm biomass in a dose-dependent manner (Figure 3). Remarkably, PNPs maintained
activity in dual-species settings and with comparable efficacy against mono-species biofilms
(Figure S6).
Selective toxicity against bacteria relative to mammalian cells is a prerequisite for therapeutic application of antimicrobial nanomaterials [14,31]. Biofilm formation at infection
sites may impede the healing process regulated by fibroblast skin cells [32]. We, therefore,
assessed biocompatibility of PNPs with mammalian NIH 3T3 fibroblasts at concentrations
used to eradicate preformed biofilms. In an in vitro co-culture study of E. coli, P. aeruginosa
and fibroblasts, PNPs showed no significant fibroblast toxicity at the relevant concentration range (Figure 4). PNPs reduced dual-species bacteria viability up to ~6-fold log10
colony-forming units at concentrations ranging from 3 to 15 µM while maintaining the
viability of mammalian fibroblast cells. This observation was comparable to the co-culture
of fibroblasts with the mono-species biofilm equivalents (Figure S7). These results suggest
safety of PNPs towards mammalian cells.
In summary, the activity of cationic antimicrobial polymeric nanoparticles against
dual-species bacterial biofilms was investigated. PNPs penetrated and accumulated across
the dense EPS matrix of dual-species biofilms. Our study has demonstrated broad-spectrum
efficacy of PNPs against dual-species biofilms with maintained fibroblast viability, whereas
the antibiotic control showed increased tolerance with low efficacy. Carefully designed
polymeric nanoparticles may address the current challenges of conventional antibiotics
as out-of-the-box therapeutics for multi-species biofilm infections. Overall, this strategy
suggests a promising alternative to combat resilient mixed-microbial biofilms with potential
clinical translatability.
4. Materials and Methods
All chemicals and solvents for syntheses were purchased from Fisher Scientific and
Sigma-Aldrich and used without further purification unless otherwise stated. The chemicals were used as received. Dichloromethane (DCM) and tetrahydrofuran (THF) were used
as solvent for chemical synthesis and dried per standard procedures. All reagents/materials
were purchased from Fisher Scientific and used as received.
The following bacteria strains were used for this study: E. coli (IDRL-10366, DH5α),
P. aeruginosa (IDRL-11442, ATCC-19660) and MRSA (IDRL-6169, IDRL-12570). Overnight
cultures of bacteria were prepared by transferring the isolated colony from the agar plate to
culture tubes with sterile media broth. The bacterial cultures were then incubated overnight
at 37 ◦ C with aeration and agitation (275 rpm) until they reached the desired growth phase.
Isolates with code IDRL were from the Infectious Diseases Research Laboratory at Mayo
Clinic. NIH-3T3 cells (ATCC CRL-1658) were purchased from ATCC. Dulbecco’s Modified
Eagle’s Medium (DMEM) (DMEM; ATCC 30-2002) and fetal bovine serum (Fisher Scientific,
SH3007103) were used for cell culture. A Pierce LDH Cytotoxicity Assay Kit was purchased
from Fisher Scientific.
4.1. Synthesis of PONI–C11 –TMA and Characterization of PNPs
To a 10 mL pear-shaped air-free flask equipped with a stir bar, 1 (1 mg, 2.51 mmol,
1.0 eq) and 4 mL of DCM were added. In a separate 10 mL pear-shaped air-free flask,
Grubbs 3rd generation catalyst (34.16 mg, 0.038 mmol, 0.02 eq) and 1 mL DCM were added.
Both flasks were sealed with septa and attached to a Schlenk nitrogen/vacuum line. Both
flasks were freeze pump-thawed three times. After thawing, Grubbs 3rd generation catalyst
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8
quantity of 10 bacterial cells /mL of GFP-expressed MRSA, DsRed-expressing E. coli or
or their combination, supplemented with 1 mM of isopropyl β-d-1-thiogalactopyranoside
their combination, supplemented with 1 mM of isopropyl β-d-1-thiogalactopyranoside
(IPTG), were seeded (2 mL in TSB) in a confocal dish and were allowed to grow. After
(IPTG), were seeded (2 mL in TSB) in a confocal dish and were allowed to grow. After 4
4 days, media were replaced by M9 media containing 1 µM of coumarin blue-tagged PNPs,
days, media were replaced by M9 media containing 1 μM of coumarin blue-tagged PNPs,
then incubated for 1 h. Biofilm samples incubated with M9 media only were used as
then incubated for 1 h. Biofilm samples incubated with M9 media only were used as concontrols. Cells were imaged before and after washing with PBS three times. Confocal
trols. Cells were imaged before and after washing with PBS three times. Confocal microsmicroscopy images were obtained on a Zeiss LSM 510 Meta microscope, from the Light Micopy images were obtained on a Zeiss LSM 510 Meta microscope, from the Light Microscroscopy Facility and Nikon Center of Excellence at the Institute for Applied Life Sciences,
copy Facility and Nikon Center of Excellence at the Institute for Applied Life Sciences,
UMass Amherst, by using a 40× objective. The settings of the confocal microscope were
UMass Amherst, by using a 40× objective. The settings of the confocal microscope were as
as follows: green channel, λex = 488 nm and λem = LP 540 nm; red channel, λex = 560 nm
follows: green channel, λex = 488 nm and λem = LP 540 nm; red channel, λex = 560 nm and
and λem = LP 640 nm; blue channel, λex = 403 nm and λem = LP 495 nm. Emission filter:
λ
em = LP 640 nm; blue channel, λex = 403 nm and λem = LP 495 nm. Emission filter: LP = high
LP
= high pass.
pass.
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4.3. Determination of Antibiofilm Activity
4.3.1. Determination of Minimum Biofilm Bactericidal Concentration (MBBC)
The MBBCs for the PNPs and antibiotic control, gentamicin, were determined using
previously established protocols [28]. Briefly, bacterial cells from overnight cultures were
diluted to 1/50th using tryptic soy broth (TSB) and incubated at 275 rpm, 37 ◦ C until they
reached mid-log phase. For mono-species biofilms, 150 µL of bacteria solution was added
to each well of a 96-well microtiter plate with pegged lids. For dual-species biofilms, 75 µL
of each component bacterial strain was added to each well of the microplates. Biofilms were
cultured by incubating the plate for 6 h in an incubator/shaker at 37 ◦ C at 50 rpm. Then,
the pegged lid was washed with 200 µL PBS for 30 s and transferred to a plate containing
two-fold serial dilutions of PONI-C11 -TMA (from 0.5 to 128 µM) and gentamicin (from 4.2
to 8500 µM) prepared in a separate 96-well plate using M9 minimal media. The plate was
incubated at 37 ◦ C for 24 h. Then, biofilms on the pegged lid were washed with PBS and
transferred to a new plate containing only M9 media. The plate was further incubated at
37 ◦ C to determine the MBBC. The MBBC of both antibiofilm agents was determined by
visual inspection and confirmed through spectrophotometry (OD600 ).
4.3.2. Treatment of Established Biofilms
Bacterial seeding solutions were prepared in TSB to reach 0.1 OD. For mono-species
biofilms, 100 µL seeding solutions were added to each well of a 96-well microtiter plate.
For dual-species biofilms, 50 µL of both bacteria seeding solutions were added to each
well of the 96-well microtiter plate. M9 medium without bacteria was used as a sterile
control. Plates were covered and incubated at room temperature under static conditions.
Biofilms were used after 2 days. They were washed with PBS (three times) to remove the
planktonic bacteria. Next, PNPs at varied concentrations, made in M9 media, were added
to each well of the microplate. The microplate was then incubated at 37 ◦ C under static
conditions. After 3 h, biofilms were washed with PBS three times, and bacterial viabilities
were determined using an Alamar Blue assay, following the manufacturer’s protocol. To
quantify the effect of PNPs on the biofilm biomass, 2-day-old biofilms were prepared and
treated as mentioned. After the 3-hour treatment, biofilms were stained with 1% crystal
violet for 15 min and solubilized with 96% ethanol. The optical density at 595 nm was
determined as a measure of biofilm mass.
4.4. Cytotoxicity Evaluation of PNPs Using Biofilm-3T3 Fibroblast Cell Coculture
The in vitro co-culture experiment was performed using a previously reported protocol [24x]. A total of 10k NIH 3T3 (ATCC CRL-1658) cells were cultured in Dulbecco’s
modified Eagle medium (DMEM; ATCC 30-2002) with 10% bovine calf serum and 1%
penicillin–streptomycin at 37 ◦ C in a humidified atmosphere of 5% CO2 . Cells were kept
for 24 h to reach a confluent monolayer. Bacteria (P. aeruginosa and E. coli) were inoculated
and harvested as mentioned above. Afterward, seeding solutions with 108 cells/mL of
each bacteria were inoculated in buffered DMEM supplemented with glucose. Old media
were removed from 3T3 cells followed by the addition of 100 µL of seeding solution (1:1
E. coli and P. aeruginosa). The co-culture was then stored in a box humidified with damp
paper towels at 37 ◦ C for 6 h without shaking. PNPs were diluted in DMEM media prior to
use to obtain the desired testing concentrations (1–15 µM). Old media were removed from
co-culture, replaced with freshly prepared testing solutions and incubated for 3 h at 37 ◦ C.
Co-cultures were then analyzed using LDH cytotoxicity assay to determine mammalian cell
viability using the manufacturer’s instructions. To determine bacteria viability in biofilms,
the testing solutions were removed and co-cultures washed with PBS. Fresh PBS was then
added, and the remaining bacteria from biofilms redispersed through sonication for 20 min
and mixing with a pipet. Solutions containing redispersed bacteria were then plated onto
LB agar plates, and colony-forming units were counted after incubation at 37 ◦ C overnight.
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4.5. Statistical Analysis
The data in biofilm penetration profiles using CLSM imaging are representative of
at least two biological replicates. For MBBC experiments, crystal violet assays, Alamar
Blue assays, fibroblast viability and quantitative colony counting, data are presented as the
mean of at least three replicates, with error bars representing standard deviation. Statistical
analysis was carried out using one-way analysis of variance (ANOVA) followed by Tukey’s
post hoc test. A p-value < 0.05 is considered as statistically significant. GraphPad Prism 5
was used to perform statistical analyses.
Supplementary Materials: The following are available online. Figure S1: Characterization of the
polymer, Figure S2: Biofilm penetration profile of polymeric nanoparticles in dual-species biofilms
before washing, Figure S3: Biofilm penetration profile of polymeric nanoparticles in DsRed-expressing
E. coli biofilm before washing, Figure S4: Biofilm penetration profile of polymeric nanoparticles in
GFP-expressing MRSA biofilm before washing, Figure S5: MBBC values of antibiotic gentamicin
against single- and multi-species biofilms, Figure S6: Biomass (crystal violet assay) and bacteria
viability (Alamar Blue assay) of single- and dual-species biofilm of MDR E. coli and MDR P. aeruginosa,
Figure S7: Viability of fibroblast and single-species biofilms in in vitro co-culture.
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